Scarica l'app Stockscreener
0.721
4.17%
-0.0314
Precedente Chiudi:
$0.7524
Aprire:
$0.77
Volume 24 ore:
116.94K
Relative Volume:
0.13
Capitalizzazione di mercato:
$2.51M
Reddito:
-
Utile/perdita netta:
$-13.47M
Rapporto P/E:
-0.0185
EPS:
-38.9215
Flusso di cassa netto:
$-8.38M
1 W Prestazione:
-6.36%
1M Prestazione:
-28.26%
6M Prestazione:
-83.65%
1 anno Prestazione:
-97.34%
Intervallo 1D:
$0.721
$0.77
Intervallo di 1 settimana:
$0.721
$0.799
Portata 52W:
$0.7052
$31.65
Artelo Biosciences Inc Stock (ARTL) Company Profile
Nome
Artelo Biosciences Inc
Settore
Industria
Telefono
858-925-7049
Indirizzo
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
0.721 | 3.52M | 0 | -13.47M | -8.38M | -38.92 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-08 | Aggiornamento | D. Boral Capital | Hold → Buy |
| 2021-02-12 | Iniziato | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Borsa (ARTL) Ultime notizie
ARTL|Artelo Biosciences Inc|Price:1.020|Chg%:-0.040 - TradingKey
Artelo Biosciences Inc (ARTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy, Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition - marketscreener.com
New Analysis of Over 50 Studies Showed that All the - GlobeNewswire
Form 4 Artelo Biosciences Inc For: 21 July By Investing.com - Investing.com South Africa
Artelo Biosciences (ARTL) awards stock options to director Douglas Blayney - Stock Titan
Artelo Biosciences (NASDAQ: ARTL) awards 136-share option to director - Stock Titan
Artelo Biosciences (ARTL) grants small stock option award to director - Stock Titan
Artelo Biosciences (ARTL) awards 136-share stock option grant - Stock Titan
Artelo Biosciences grants options to director | ARTL Insider Trading - Stock Titan
Artelo Biosciences Q4 2025 Earnings: EPS Surprises Significantly vs. EstimatesRetail Earnings Report - dars.gov.et
Artelo Biosciences (ARTL) Proxy filing Summary - Quartr
Artelo Biosciences (NASDAQ: ARTL) details 2026 director and shareholder vote tallies - Stock Titan
Artelo Biosciences (ARTL) AGM 2026 Summary - Quartr
ARTL: All proposals, including director elections and share increases, were approved - TradingView
Artelo Biosciences Company Profile & Introduction - Moomoo
Artelo presents preclinical data on osteoarthritis pain drug - Investing.com UK
Artelo Biosciences (ARTL) Advances ART26.12 for Osteoarthritis P - GuruFocus
Artelo Biosciences, Inc. Announces Results from Nonclinical Osteoarthritis Study Supporting ART26.12 as Potential First-In-Class New Therapy for Chronic Pain Conditions - marketscreener.com
Artelo Biosciences Announces Preclinical Data Supporting ART26.12 for Osteoarthritis Pain with Reduced Gastric Damage Compared with Naproxen - Quiver Quantitative
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions - The Manila Times
These stocks are moving in today's after hours session - ChartMill
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 - The Manila Times
Every Artelo proxy helps reach quorum for July 17 meeting - Stock Titan
Artelo reports positive neuropathic pain study results for ART27.13 - Investing.com UK
Artelo reports ART27.13 pain study results - grafa.com
Artelo Biosciences (ARTL) Reports Positive Findings on Pain Trea - GuruFocus
Artelo reports positive neuropathic pain study results for ART27.13 By Investing.com - Investing.com India
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy - The Manila Times
Artelo Biosciences Announces ART27.13 Data Suggest Potential Benefit for Neuropathic Pain in Cancer Patients - Quiver Quantitative
Cancer pain study: ART27.13 eases nerve pain signs in paclitaxel-treated animals - Stock Titan
Artelo Biosciences regains Nasdaq listing compliance - Investing.com
ARTELO BIOSCIENCES INC (ARTL) Stock Chart - ChartMill
ARTLArtelo Biosciences Inc Latest SEC Filings - Finviz
Artelo Biosciences (ARTL) Reveals Positive Preclinical Data in N - GuruFocus
Artelo Biosciences Announces New Data Support - Moomoo
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury - Yahoo Finance
Artelo presents research on FABP5 inhibitor ART26.12 - Investing.com UK
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 - The Manila Times
Artelo Biosciences Reports Multi-Omics Findings Highlighting Linoleic Acid Link in ART26.12 FABP5 Inhibition - Quiver Quantitative
Artelo says its FABP5 inhibitor hits a key lipid pathway across disease models - Stock Titan
Artelo presents phase 1 data for FABP5 inhibitor ART26.12 - Investing.com UK
Artelo Biosciences Presents Clinical And Biomarker Data Supportive Of The Development Of ART26.12 And Follow-On FABP5 Inhibitors - marketscreener.com
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 - The Manila Times
Artelo presents phase 1 data for FABP5 inhibitor ART26.12 By Investing.com - Investing.com Canada
Artelo Biosciences Reports Positive First-in-Human ART26.12 Safety and Pharmacokinetic Results, Advances AI-Enabled Biomarker Research - Quiver Quantitative
Artelo’s first-in-human FABP5 inhibitor shows tolerability, biomarker signals - Stock Titan
Artelo Biosciences Inc Actuals & Estimates (NASDAQ:ARTL) - TradingView
Artelo Biosciences Inc (ARTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why JOYY shares are trading higher by 12%; here are 20 stocks moving premarket - MSN
Artelo Biosciences Inc Azioni (ARTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.84%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):